Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Suboptimal concentrations of Ceftazidime/Avibactam (CAZ-AVI) may select for resistance to CAZ-AVI in extensively drug- resistant Pseudomonas aeruginosa: In vivo and in vitro evidence.

ABSTRACT: Suboptimal concentrations of Ceftazidime/Avibactam (CAZ-AVI) may select for resistance to CAZ-AVI in extensively drug- resistant Pseudomonas aeruginosa: In vivo and in vitro evidence.

PROVIDER: PRJEB55650 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Suboptimal concentrations of Ceftazidime/Avibactam (CAZ-AVI) may select for resistance to CAZ-AVI in extensively drug- resistant Pseudomonas aeruginosa: In vivo and in vitro evidence.

Project description:Suboptimal concentrations of Ceftazidime/Avibactam (CAZ-AVI) may select for resistance to CAZ-AVI in extensively drug- resistant Pseudomonas aeruginosa: In vivo and in vitro evidence.

| PRJEB55649 | ENA

Transcriptomics analysis during the transient ceftazidime tolerance of Burkholderia pseudomallei

Project description:B. pseudomallei strain K96243 is sensitive to the drug ceftazidime (CAZ), but has been shown to exhibit transient CAZ tolerance when in a biofilm form. To investigate an observed shift in gene expression profile during ceftazidime (CAZ) tolerance and to better understand the mechanistic aspects of this transient tolerance, RNA-sequencing was performed on B. pseudomallei K96243 from the following three growth states: planktonic-free, biofilm, and planktonic shedding cells. Results indicated that the expression of 651 genes (10.97%) were significantly changed in both biofilm (resistant) and planktonic shedding (sensitive) cells in comparison to the planktonic state. Burkholderia biofilm shifts its transcriptome in response to ceftazidime exposure by regulating iron-sulfur stabilizing and metabolic-related genes.

2021-06-30 | GSE168275 | GEO

Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence.

Project description:This study correlates in vivo findings in a patient with an extensively drug-resistant (XDR) P. aeruginosa infection who developed resistance to ceftazidime-avibactam (CAZ-AVI) with in vitro results of a 7-day hollow-fiber infection model (HFIM) testing the same bacterial strain. The patient was critically ill with ventilator-associated pneumonia caused by XDR P. aeruginosa ST175 with CAZ-AVI MIC of 6 mg/L and was treated with CAZ-AVI in continuous infusion at doses adjusted for renal function. Plasma concentrations of CAZ-AVI were analyzed on days 3, 7, and 10. In the HIFM, the efficacy of different steady-state concentrations (Css) of CAZ-AVI (12, 18, 30 and 48 mg/L) was evaluated. In both models, a correlation was observed between the decreasing plasma levels of CAZ-AVI and the emergence of resistance. In the HIFM, a Css of 30 and 48 mg/L (corresponding to 5× and 8× MIC) had a bactericidal effect without selecting resistant mutants, whereas a Css of 12 and 18 mg/L (corresponding to 2× and 3× MIC) failed to prevent the emergence of resistance. CAZ/AVI resistance development was caused by the selection of a single ampC mutation in both patient and HFIM. Until further data are available, strategies to achieve plasma CAZ-AVI levels at least 4× MIC could be of interest, particularly in severe and high-inoculum infections caused by XDR P. aeruginosa with high CAZ-AVI MICs.

| S-EPMC9686790 | biostudies-literature

Whole-Genome Sequencing of Ceftazidime-Avibactam resistant KPC-producing Klebsiella pneumoniae strains

Project description:Emergence of Ceftazidime-Avibactam resistant KPC-producing K. pneumoniae (KPC-Kp) during ceftazidime-avibactam-based antimicrobial treatment.

| PRJEB21871 | ENA

Susceptibility to ceftazidime/avibactam in German MDR/XDR Pseudomonas aeruginosa

Project description:Susceptibility to ceftazidime/avibactam in German MDR/XDR Pseudomonas aeruginosa

| PRJEB30639 | ENA

undefined

Project description:CNB CAZ CAZ/AVI

| PRJEB58901 | ENA

Novel Mechanisms of Antibiotic Resistance in Mismatch Repair-Deficient Pseudomonas aeruginosa hypermutators

Project description:Using in vitro directed evolution, we show that mismatch repair-deficient Pseudomonas aeruginosa can engage novel resistance mechanisms to ceftazidime-avibactam.

2021-08-30 | GSE180086 | GEO

Ceftazidime-Avibactam plus Aztreonam Cocktail for the Treatment of VIM-Producing Pseudomonas aeruginosa Infections.

Project description:Ceftazidime-Avibactam plus Aztreonam for the Treatment of VIM-Producing Pseudomonas aeruginosa Infections.

| PRJEB81449 | ENA

Laboratory-selected mutants of Enterobacteriaceae with resistance or diminished susceptibility to ceftazidime/avibactam

Project description:Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae

| PRJEB27344 | ENA

Synergy between mecillinam and ceftazidime/avibactam or avibactam against multi-drug resistant carbapenemase-producing Escherichia coli and Klebsiella pneumoniae.

Project description:Mecillinam/avibactam synergy

| PRJEB50806 | ENA